Related Experiment Video
Updated: Jul 24, 2025
Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure
Published on: January 18, 2021
MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.
Jennifer M Mitchell1, Michael Bogenschutz1, Alia Lilienstein1
1Department of Neurology, University of California San Francisco, San Francisco, CA, USA. Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA. Department of Psychiatry, New York University Grossman School of Medicine, New York, NY, USA. Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, USA. MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA. Kleiman Consulting and Psychological Services, Sayreville, NJ, USA. KPG Psychological Services LLC, Brunswick, ME, USA. Aguazul-Bluewater Inc., Boulder, CO, USA. MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA. Nautilus Sanctuary, New York, NY, USA. Fluence, Woodstock, NY, USA. Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Medical University of South Carolina, Charleston, SC, USA. San Francisco Insight and Integration Center, San Francisco, CA, USA. British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada. Boston University School of Medicine, Boston, MA, USA. Chaim Sheba Medical Center, Tel HaShomer, Israel. Ray Worthy Psychiatry LLC, New Orleans, LA, USA. Wholeness Center, Fort Collins, CO, USA. New School Research LLC, North Hollywood, CA, USA. Zen Therapeutic Solutions, Mt Pleasant, SC, USA. University of Toronto, Toronto, Ontario, Canada. Dr Simon Amar Inc., Montreal, Quebec, Canada. Be'er Ya'akov Ness Ziona Mental Health Center, Be'er Ya'akov, Israel. Stanford School of Medicine, Stanford, CA, USA.
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy significantly improved severe post-traumatic stress disorder (PTSD) symptoms and functional impairment compared to placebo. This novel PTSD treatment was found to be safe and well-tolerated in a phase 3 clinical trial.
Area of Science:
- Psychiatry
- Clinical Psychology
- Pharmacology
Background:
- Post-traumatic stress disorder (PTSD) is a significant public health concern with limited treatment efficacy.
- Existing therapies for severe PTSD, including those with comorbidities, often yield modest results.
Purpose of the Study:
- To evaluate the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for severe PTSD.
- To assess MDMA's impact on PTSD symptoms and functional impairment in a diverse patient population.
Main Methods:
- A randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) involving 90 participants.
- Participants received manualized therapy with either MDMA or placebo, alongside preparatory and integrative therapy sessions after medication washout.
- Primary endpoint: Clinician-Administered PTSD Scale for DSM-5 (CAPS-5); Secondary endpoint: Sheehan Disability Scale (SDS).
Main Results:
- MDMA-assisted therapy demonstrated significant and robust reduction in CAPS-5 scores compared to placebo (P < 0.0001, d = 0.91).
- A significant decrease in SDS total score was observed in the MDMA group (P = 0.0116, d = 0.43).
- MDMA did not show adverse events related to abuse potential, suicidality, or QT prolongation, indicating a favorable safety profile.
Conclusions:
- MDMA-assisted therapy is highly efficacious and well-tolerated for severe PTSD, including patients with common comorbidities.
- This treatment represents a potential breakthrough for PTSD, warranting expedited clinical evaluation.
- The study supports MDMA-assisted therapy as a promising new therapeutic option for individuals suffering from severe PTSD.
Related Concept Videos
01:26Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
01:27Post-traumatic Stress Disorder
Symptoms and Behavioral Manifestations
A spectrum of distressing symptoms characterizes PTSD. Recurrent flashbacks, where individuals involuntarily relive traumatic events,...
01:30Electroconvulsive Therapy